Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)

• Published in: Clinical diabetes Vol. 41; no. 3; pp. 425 - 434
• Main Authors: Edelman, Steven, Goldman, Jennifer, Malone, Daniel C, Preblick, Ronald, Munaga, Kovida, Li, Xuan, Gill, Jasvinder, Gangi, Sumana
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01-07-2023
• Subjects: Diabetes; Disease management; Glucose; Glycemic index; Hypoglycemia; Insulin
• ISSN: 0891-8929; 1945-4953
• DOI: 10.2337/cd22-0096

People with type 2 diabetes receiving a second-generation basal insulin (BI) analog may be switched to a first-generation formulation for financial reasons or changes in health insurance. However, because second-generation BI analogs have more even pharmacokinetic profiles, longer durations of action (>24 vs. ≤24 hours), and more stable action profiles than first-generation BI analogs, such a change may result in suboptimal treatment persistence and/or adherence. This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI. The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI.